Method to treat premature ejaculation in humans
The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.
1. A method of effectively treating a sexual dysfunction in humans or other mammals, comprising administering to a patient in need of such treatment an amount of agents including a) an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof, and b) a μ-opiate receptor agonist, partial agonist or agonist/antagonist, or a pharmaceutically acceptable salt thereof, whereby the combined amount of said agents is effective to treat the sexual dysfunction.
2. The method of claim 1 , wherein the sexual dysfunction is premature ejaculation.
3. The method of claim 1 , wherein the agents are administered separately.
4. The method of claim 1 , wherein the agents are administered in combination.
5. The method of claim 1 , wherein the agents are administered prior to sexual activity.
6. The method of claim 1 , wherein the agents are administered orally, by means of an implant, parenterally, sub-dermally, sublingually, rectally, topically, or via inhalation.
7. The method of claim 6 , wherein the agents are administered orally.
8. The method of claim 1 , wherein the NMDA receptor antagonist is dextromethorphan, dextrorphan, ketamine, amantadine, memantine, eliprodil, ifenprodil, phencyclidine, MK-801, dizocilpine, CCPene, flupirtine, or derivatives or salts thereof.
9. The method of claim 8 , wherein the NMDA receptor antagonist is dextromethorphan.
10. The method of claim 1 , wherein the a μ-opiate receptor agonist, partial agonist or agonist/antagonist is any one of (1R, 2R or 1S, 2S)-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol (tramadol), its N-oxide derivative (“tramadol N-oxide”), and its O-desmethyl derivative (“O-desmethyl tramadol”) or mixtures, stereoisomers or recemates thereof.
11. The method of claim 10 , wherein the μ-opiate receptor agonist, partial agonist or agonist/antagonist is tramadol.
12. The method of claim 1 wherein the agents are administered in a dosage form selected from the group consisting of a tablet, a multiparticulate formulation for oral administration; a solution, a sustained release formulation, a suspension or elixir for oral administration, an injectable formulation, an implantable device, a topical preparation, a transdermal delivery device, a suppository, a buccal tablet, and an inhalation formulation.
13. The method of claim 12 , wherein the dosage form is further defined as a solid oral dosage form formulated as a tablet or capsule.
14. The method of claim 1 , wherein the ratio of NMDA receptor antagonist to .mu.-opiate receptor agonist, partial agonist or agonist/antagonist is from about 15:1 to 1:15.
15. The method of claim 14 , wherein the ratio of NMDA receptor antagonist to .mu.-opiate receptor agonist, partial agonist or agonist/antagonist is from about 10:1 to 1:10.
16. The method of claim 1 , wherein a cytochrome P450 inhibitor, or a pharmaceutically acceptable salt thereof, is included as an agent.
17. The method of claim 16 , wherein the cytochrome P450 inhibitor is a debrisoquin hydroxylase inhibitor.
18. The method of claim 16 wherein the cytochrome P450 inhibitor is quinidine, quinine, naphthyridine, xanthine, phenoxy amino alkane, carbamoyl imidazole, a guanidine imidazole, cimetidine (N-cyano-N′-methyl-N″-[2[[(5-methyl-1H-imidazol-4 yl)methyl ]thio]ethyl]guanidine), a quinoline, chloroquine (7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline), primaquine (8-(4-amino-1-methylbutylamino)-6-methoxyquinoline), a trifluoromethyl oxime ether, fluvoxamine, also known as 5-methoxy-1[4-(trifluoromethyl)-phenyl]-1 pentanone 0-(2-aminoethyl) oxime, or pharmaceutically acceptable salts thereof.
19. The method of claim 1 , wherein caffeine is included as an agent.
20. A pharmaceutical composition comprising a therapeutically effective amount of a combination of agents, the combination comprising a) an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof, b) a μ-opiate receptor agonist, partial agonist or agonist/antagonist, or a pharmaceutically acceptable salt thereof, and c) a cytochrome P450 inhibitor, or a pharmaceutically acceptable salt thereof.